Shattering barriers toward clinically meaningful MSC therapies

More than 1050 clinical trials are registered at FDA.gov that explore multipotent mesenchymal stromal cells (MSCs) for nearly every clinical application imaginable, including neurodegenerative and cardiac disorders, perianal fistulas, graft-versus-host disease, COVID-19, and cancer. Several companie...

Full description

Saved in:

Bibliographic Details
Published in:	Science advances Vol. 6; no. 30; p. eaba6884
Main Authors:	Levy, Oren, Kuai, Rui, Siren, Erika M J, Bhere, Deepak, Milton, Yuka, Nissar, Nabeel, De Biasio, Michael, Heinelt, Martina, Reeve, Brock, Abdi, Reza, Alturki, Meshael, Fallatah, Mohanad, Almalik, Abdulaziz, Alhasan, Ali H, Shah, Khalid, Karp, Jeffrey M
Format:	Journal Article
Language:	English
Published:	United States American Association for the Advancement of Science 01-07-2020
Subjects:	Applied Sciences and Engineering Batch Cell Culture Techniques - methods Betacoronavirus Bioreactors Coronavirus Infections - therapy Coronavirus Infections - virology COVID-19 Graft vs Host Disease - therapy Health and Medicine Humans Mesenchymal Stem Cell Transplantation - methods Mesenchymal Stem Cells - metabolism Metabolic Engineering - methods Pandemics Pneumonia, Viral - therapy Pneumonia, Viral - virology Review Reviews SARS-CoV-2 SciAdv reviews Transplant Recipients
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	More than 1050 clinical trials are registered at FDA.gov that explore multipotent mesenchymal stromal cells (MSCs) for nearly every clinical application imaginable, including neurodegenerative and cardiac disorders, perianal fistulas, graft-versus-host disease, COVID-19, and cancer. Several companies have or are in the process of commercializing MSC-based therapies. However, most of the clinical-stage MSC therapies have been unable to meet primary efficacy end points. The innate therapeutic functions of MSCs administered to humans are not as robust as demonstrated in preclinical studies, and in general, the translation of cell-based therapy is impaired by a myriad of steps that introduce heterogeneity. In this review, we discuss the major clinical challenges with MSC therapies, the details of these challenges, and the potential bioengineering approaches that leverage the unique biology of MSCs to overcome the challenges and achieve more potent and versatile therapies.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-2 These authors equally contributed to this work.
ISSN:	2375-2548 2375-2548
DOI:	10.1126/sciadv.aba6884